AIM ImmunoTech Inc. 近日宣布,其在UPMC开展的针对复发性卵巢癌的二期临床试验取得了令人瞩目的中期结果。数据显示,该试验达到了50%的客观缓解率(ORR),这一积极信号强烈暗示了其研究药物在联合疗法中可能具备突破性的治疗潜力。
AIM ImmunoTech Inc. 近日宣布,其在UPMC开展的针对复发性卵巢癌的二期临床试验取得了令人瞩目的中期结果。数据显示,该试验达到了50%的客观缓解率(ORR),这一积极信号强烈暗示了其研究药物在联合疗法中可能具备突破性的治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.